In the first paper, researchers from the Fred Hutchinson Cancer Research Institute in Seattle took haematopoeic stem cells (HSCs), bone-marrow cells that are the progenitors of all blood cells, from two pigtail macaque monkeys and transformed them genetically by splicing an inserted gene sequence for mC46 into their CCR5 receptor gene.

They then injected the cells back into the monkeys. One monkey had 20%of its HSCs replaced by the C34-producing cells and the second had over 50% replaced.

A week later, they infected them and two control monkeys with a particularly lethal strain of genetically engineered human/monkey SHIV, which destroys CD4 cells fast and usually develops a steady-state viral load in the order of several million copies/ml.

In the control animals, their CD4 counts declined from around 600 cells/mm3 before infection to between 10 and 50 cells/mm3 within two to three weeks. In the monkeys with mC46, the CD4 cell count dipped to about 100 cells/mm3 within two weeks of infection, but then rose slowly back to pre-infection levels over the next six months.

At the time of highest SHIV viral load and fewest CD4 cells, 90% of the CD4 cells in the mC46 monkeys had the fusion-inhibitor-generating insert in them, which is what one would expect, given that SHIV so decimates non-mutated CD4 cells.

What was unexpected to the scientists, though, was that after the period of peak viral load, the non-mutated CD4 cells made a partial recovery in one monkey to about 60% of all CD4 cells and in the other about 20%. This is promising, as it shows that one would not need to replace all or even most of the CD4 cells in the body with HIV-resistant ones in order to contain an HIV infection, and that increasing numbers of non-resistant cells does not lead to a new burst of virus.

This may also mean that it would not be necessary to take the dangerous step of having to destroy a persons immune system with whole-body radiation, as happened to the 'Berlin patient' Timothy Ray Brown, in order for the new cells to repopulate the immune system.

As we said, SHIV reproduces furiously and peak viral load in all monkeys ten days after infection was one billion copies/ml. After that, viral load in the control monkeys declined to about half a million in one and about ten million in the other. In the mC46 monkeys, it fell to about 100,000 in the monkey with 20% of its cells replaced by mC46 cells and down to a few hundred in the one with more than 50% of its cells replaced.

Viral load was about 320-fold lower (2.5 logs) in the first monkey and about 1400-fold (3.15 logs) lower in the second. This would transform a typical HIV viral load in an untreated human of 70,000 copies/ml to 50 copies/ml before any ARVs were taken.

Although there was a partial recovery of unmutated CD4 cells in the blood, memory cells in the lymph nodes that form the reservoir of proviral HIV DNA remained predominantly the HIV-resistant mC46 cells, which is exactly where one would want them to be.

Original post:
Gene therapy studies show potential for HIV control without drugs

Recommendation and review posted by Bethany Smith

By Lisa Raffensperger | March 13, 2013 1:22 pm

Most people who live to old age will suffer from arthritis. The conditions prevalence is growing alongside a graying world population.

However the only treatments at the moment address the symptoms rather than the causethe loss of cartilage in joints. Joint replacement is a last-ditch solution for some sufferers. Now a gene therapy approach has demonstrated promise in staving off arthritis in mice, opening the door to human testing.

The inspiration for the research came from studying children with a genetic form of arthritis that strikes early. These children are deficient in the gene for a protein called lubricin. Lubricin is thought to act as a lubricant between the bones in a joint.

Since a lack of lubricin caused arthritis, researchers thought perhaps additional lubricin could stave it off.

They tested this hypothesis by creating a strain of mice with an additional lubricin gene in their DNA. When these mice suffered an injury to their knees they didnt develop injury-induced arthritis. Inspection of the mices joints found that their cartilage resembled mice whod never been injured in the first place. Non-modified mice, on the other hand, had symptoms of arthritis just a month after injury.

Whats more, as the mice that made extra lubricin aged, their cartilage stayed youthful. That suggests the protein may protect against both common forms of arthritis: injury-related and age-related.

The treatment also works if the replacement genes are injected right into the joint itself, the researchers report in Science Translational Medicine today. Its delivery to human patients, then, could be similar to the injection of joint lubricants that some arthritis sufferers currently rely on.

However no gene therapies are currently approved by the FDA for human treatment, so this research will likely stay in the lab for some time yet.

More:
Gene Therapy Could Prevent Arthritis

Recommendation and review posted by Bethany Smith

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/2nfn6s/gene_therapy) has announced the addition of Jain PharmaBiotech's new report "Gene Therapy - Technologies, Markets and Companies" to their offering.

Gene therapy can be broadly defined as the transfer of defined genetic material to specific target cells of a patient for the ultimate purpose of preventing or altering a particular disease state. Genes and DNA are now being introduced without the use of vectors and various techniques are being used to modify the function of genes in vivo without gene transfer. If one adds to this the cell therapy particularly with use of genetically modified cells, the scope of gene therapy becomes much broader. Gene therapy can now combined with antisense techniques such as RNA interference (RNAi), further increasing the therapeutic applications. This report takes broad overview of gene therapy and is the most up-to-date presentation from the author on this topic built-up from a series of gene therapy report written by him during the past decade including a textbook of gene therapy and a book on gene therapy companies. This report describes the setbacks of gene therapy and renewed interest in the topic

Gene therapy technologies are described in detail including viral vectors, nonviral vectors and cell therapy with genetically modified vectors. Gene therapy is an excellent method of drug delivery and various routes of administration as well as targeted gene therapy are described. There is an introduction to technologies for gene suppression as well as molecular diagnostics to detect and monitor gene expression.

Clinical applications of gene therapy are extensive and cover most systems and their disorders. Full chapters are devoted to genetic syndromes, cancer, cardiovascular diseases, neurological disorders and viral infections with emphasis on AIDS. Applications of gene therapy in veterinary medicine, particularly for treating cats and dogs, are included.

Research and development is in progress in both the academic and the industrial sectors. The National Institutes of Health (NIH) of the US is playing an important part. As of 2012, over 2030 clinical trials have been completed, are ongoing or have been approved worldwide.A breakdown of these trials is shown according to the areas of application.

Since the death of Jesse Gelsinger in the US following a gene therapy treatment, the FDA has further tightened the regulatory control on gene therapy. A further setback was the reports of leukemia following use of retroviral vectors in successful gene therapy for adenosine deaminase deficiency. Several clinical trials were put on hold and many have resumed now. The report also discusses the adverse effects of various vectors, safety regulations and ethical aspects of gene therapy including germline gene therapy.

The markets for gene therapy are difficult to estimate as there is only one approved gene therapy product and it is marketed in China since 2004. Gene therapy markets are estimated for the years 2012-2022. The estimates are based on epidemiology of diseases to be treated with gene therapy, the portion of those who will be eligible for these treatments, competing technologies and the technical developments anticipated in the next decades. In spite of some setbacks, the future for gene therapy is bright.The markets for DNA vaccines are calculated separately as only genetically modified vaccines and those using viral vectors are included in the gene therapy markets

Profiles of 179 companies involved in developing gene therapy are presented along with 203 collaborations. There were only 44 companies involved in this area in 1995. In spite of some failures and mergers, the number of companies has increased more than 4-fold within a decade. These companies have been followed up since they were the topic of a book on gene therapy companies by the author of this report. John Wiley & Sons published the book in 2000 and from 2001 to 2003, updated versions of these companies (approximately 160 at mid-2003) were available on Wiley's web site. Since that free service was discontinued and the rights reverted to the author, this report remains the only authorized continuously updated version on gene therapy companies.

Benefits of this report

Originally posted here:
Research and Markets: Gene Therapy : Technologies, Markets and Companies 2013 Update with Added Company Profiles

Recommendation and review posted by Bethany Smith

Stem Cell Treatment for Spinal Cord Injury at the Stem Cell Institute in Panama - Daniel Campbell
After stem cell therapy at the Stem Cell Institute in Panama, Daniel Campbell describes how his condition has improved since his first treatment. Daniel is i...

By: cellmedicine

See more here:
Stem Cell Treatment for Spinal Cord Injury at the Stem Cell Institute in Panama - Daniel Campbell - Video

Recommendation and review posted by sam

Dr Alok Sharma Stem Cell Therapy Treatment for Muscular Dystrophy
Dr Alok Sharma Stem Cell Therapy Treatment for Muscular Dystrophy She is a known case of MD with history of gradual onset of progressive lower extremities muscle weakness noticed since 27 years of age with complaints of imbalance while walking foot drop and difficulty in stair case climbing So she was investigated and muscle biopsy confirmed diagnosis of MD After Stem Cell Therapy 1 Stamina has increased Exercise tolerance has improved 2 She can lift her leg more up while in standing 3 Hip ...

By: neurogenbsi

Read more:
Dr Alok Sharma Stem Cell Therapy Treatment for Muscular Dystrophy - Video

Recommendation and review posted by Bethany Smith

Dr Alok Sharma Stem Cell Therapy Treatment for Cerebral Palsy
Dr Alok Sharma Stem Cell Therapy Treatment for Cerebral Palsy He is a known case of Diplegic CP with history of full term normal delivery (vaccum) delivery a...

By: neurogenbsi

Read the rest here:
Dr Alok Sharma Stem Cell Therapy Treatment for Cerebral Palsy - Video

Recommendation and review posted by Bethany Smith

With its growing popularity in the country, the so-called stem cell therapy, which was recently approved by the Department of Health (DOH), is now available in Davao City.

Dr. Luz Acosta, a Davao-born physician specializing in Ophthalmology, Oculoplastic Reconstructive Surgery, Cosmetic Surgery and recently Stem Cell Treatment, conducts the procedure after acquiring equipment from Australia and the USA. She is supported by a team that includes cardiologists, internists, and anesthesiologists who administer the laboratory tests and cardiopulmonary clearance to determine if an individual can safely undergo stem cell therapy. Having trained in this discipline abroad, she recently decided to offer this treatment after it was approved by the DoH.

As a founding member of the Philippine Society for Stem Cell Medicine that was only established last January 18, 2013 with DOH Sec. Dr. Enrique Ona as its honorary chair, Acosta is joined by doctors Jose Sabili, Melchor Santos, Christian Mancao, Leo Olarte, Bu Castro, Oscar Tinio, and Almond Derla as well as Mr. Rico Colayco as organizers of the society.

"This means that the Philippine Society for Stem Cell Medicine is the regulating body for the practice of stem cell treatment in the country," Acosta says. "Stem cell therapy is legal and safe for every medically cleared patient who wants to undergo such treatment to be rejuvenated and treated of his/her illnesses and diseases."

Acosta said that based on what was stipulated in the approved directions for stem cell therapy, the stem cell could just come from the person himself and not from the other sources like black sheep or aborted fetus, adding that sources of stem cells are fats, blood, bone marrow and umbilical cord.

"It could take five to six hours for one to undergo stem cell therapy. Harvesting is done in the first two hours, then another one to two hours for stem cell processing and activation, and the last one to two hours for treatment of stem cells back to the same patient," she said.

Popular personalities who have already publicly admitted that they had undergone stem cell therapy are former President Joseph Estrada, Senate President Juan Ponce Enrile and former Senator Ernesto Maceda, who said that they spent millions to pay for the treatment.

But Acosta said that it could be a lot cheaper here than abroad, as the cost of treatment will be in accordance to the guidelines of the Phil. Society for Stem Cell Medicine.

She said there have been very good clinical outcomes from stem cell treatments on autism, auto-immune diseases, cerebral palsy, diabetes, heart disease, liver cirrhosis, macular degeneration, multiple sclerosis, nerve damage, osteoarthritis, spinal cord injury and stroke.

"But we have to clarify here that we are not claiming stem cell therapy as a cure for cancer, though it can alleviate pain and improve patients' wellbeing while undergoing cancer therapy," she said.

Read the original post:
Stem Cell Therapy Now In Davao

Recommendation and review posted by Bethany Smith

HARRISBURG The Center for Rural Pennsylvania has re-elected state Senator Gene Yaw, R-23 of Lycoming County, to serve as Chairman of its 11 member Board of Directors.

The Center is a bipartisan, bicameral legislative agency that serves as a resource for rural policy within the Pennsylvania General Assembly.

I am again very humbled to be re-elected Chairman of the Board for the Center for Rural Pennsylvania, said Yaw. As a state Senator and resident of rural Pennsylvania, I find the research and reports conducted and distributed by the Center for Rural Pennsylvania invaluable to our work in Harrisburg and also to many individuals, groups and organizations in my district, and across the Commonwealth.

The Center works with the legislature, educators, state and federal executive branch agencies, and national, statewide, regional and local organizations to maximize resources and strategies that can better serve Pennsylvanias 3.4 million rural residents.

Approximately 27 percent of the states 12.7 million residents live in 48 rural counties, Yaw added. By 2030, Pennsylvania rural counties are projected to have a total population of 3.57 million people, a 3 percent increase from 2010. This further amplifies the importance of the work provided by the Center for Rural Pennsylvania.

Created in 1987 under Act 16, the Rural Revitalization Act, the Center for Rural Pennsylvania promotes and sustains the vitality of Pennsylvanias rural and small communities by:

- Sponsoring research projects to identify policy options for legislative and executive branch consideration and action

- Collecting data on trends and conditions to understand the diversity of rural Pennsylvania

- Publishing information and research results to inform and educate audiences about the diverse people and communities of rural Pennsylvania; and

- Participating in local, state and national forums on rural issues to present and learn from best practices.

Read the original post:
State Sen. Gene Yaw re-elected board chairman for Center for Rural Pennsylvania

Recommendation and review posted by Bethany Smith

March 12, 2013 - News Release

A discovery by University of Guelph researchers will help in understanding how horses develop recurrent airway obstruction (RAO) and offers hope of potential solutions for people with asthma.

In a paper in a recent issue of BMC Genomics, the researchers discuss their discovery that horses have three copies of a gene normally found as a single copy in mammals. This gene, called secretoglobin family 1A member 1 (SCGB-1A1), produces a protein secreted in large amounts in the airway.

RAO is a chronic inflammatory lung disease. It is especially prevalent during winter in horses kept in barns and fed hay. The researchers found that RAO-susceptible horses have much less SCGB1A1 protein in their airways, which enhances inflammation.

Symptoms in horses with RAO resemble those of humans with environmentally induced asthma.

The researchers found that two of the gene copies could play a significant role in treating RAO. The third copy has no recognized function and may have evolved into a pseudo-gene.

Lead author Olivier Ct, a PhD candidate in the Department of Pathobiology, says the study could have larger implications than treating horses.

Were able to use the horse as a model for asthma in humans, said Ct. We found through our research that horses suffering from RAO had reduced SCGB1A1 levels. Since an obvious suggestion for treating RAO is to increase protein levels of SCGB1A1, we made a synthetic version of it in the lab. We are currently testing the proteins function. While it would not be possible to simply provide humans with this protein to reduce asthma, as humans and horses are different species, these findings do give hope that we can find novel treatments for asthma.

Study co-author Prof. Dorothee Bienzle said it was challenging to isolate and assess the individual genes. The researchers also faced challenges because of the unusual nature of the gene triplication.

Other mammals do not have multiple SCGB1A1 copies, except for some other equidae, such as Przewalskis horses and donkeys, she said. So it is difficult to know where the gene came from. We can speculate that it was an evolutionary response that took place over many years. We dont know why the pseudo-gene exists or what its purpose is. The distribution of the other two gene transcripts and proteins indicates they are extremely prevalent in the lung and reproductive organs.

Originally posted here:
Horse Gene Discovery Points to Asthma Relief: Guelph Study

Recommendation and review posted by Bethany Smith

GIANT GENETIC MUTANT RATS 2013
WERE THEY RELEASED THERE? ARE THEY INFECTED WITH HORRIBLE DISEASES? THIS SOUNDS VERY SUSPICIOUS TO ME! LINK: http://www.ibtimes.co.uk/articles/437326/2013022...

By: faceintree

See more here:
GIANT GENETIC MUTANT RATS 2013 - Video

Recommendation and review posted by Bethany Smith

Palo Alto and Berkeley, Calif. March 10, 2013 An unprecedented collaboration among academia, industry, government and civil society has resulted in the launch of a professional-grade collection of public domain DNA parts that greatly increases the reliability and precision by which biology can be engineered. Researchers at the International Open Facility Advancing Biotechnology (aka, BIOFAB) have just announced that they have, in effect, established rules for the first language for engineering gene expression, the layer between the genome and all the dynamic processes of life. The feat is all the more remarkable considering that just a few years ago several prominent scientists claimed that it would be impossible to develop frameworks enabling reliably reusable standard biological parts. Collectively, the BIOFAB team has produced thousands of high quality standard biological parts. The DNA sequences that encode all parts and the data about them are free and available online.

The project is detailed in three research papers, Precise and Reliable Gene Expression via Standard Transcription and Translation Initiation Elements, and Quantitative Estimation of Activity and Quality for Collections of Functional Genetic Elements, published simultaneously in Nature Methods, and Measurement and Modeling of Intrinsic Transcription Terminators, forthcoming in Nucleic Acids Research (see full citations below).

The BIOFABs rules for engineering expression come in the form of mathematical models that can be used to predict and characterize the individual parts used in synthetic biology. The work establishes a much-needed technological foundation for the field, allowing researchers to engineer the function of DNA more precisely, and to better predict the resultant behavior.

Dr. Vivek Mutalik, a BIOFAB team leader, says that synthetic biology has been plagued by a lack of reliability and predictability. Until now, virtually every project has been a one-off we havent figured out how to standardize the genetic parts that are the building blocks of this new field. Researchers produce amazing new parts all the time, but much like trying to use someone elses house key in your own door, its been difficult to directly reuse parts across projects. Without the ability to characterize parts that is, to understand how they will behave in multiple contexts biotech researchers are doomed to a lengthy process of trial-and-error. Fortunately, notes Mutalik, Our work in the BIOFAB changes all that.

The plan for establishing the rules for how genetic parts fit together was ambitious and complex. First, researchers needed to figure out the functional patterns of genetic parts. They had to ask, To what extent do the basic genetic parts that control gene expression misbehave when reused over and again in novel combinations, said Mutalik. BIOFAB researchers had to make and test hundreds of combinations of frequently used parts, then take the resulting data and build mathematical models that demonstrated part quality. Joao Guimaraes, a member of the BIOFAB team and graduate student in computational biology, explains that difficult-to-predict parts are deemed to be low quality, while high quality parts behave the same when reused. Once they found a way to determine part quality, the BIOFAB team set to work on establishing rules for precision control of gene expression, a process that underlies all of biotechnology. They learned by observing natural examples of genetic junctions, and built reliable transcription and translation initiation elements. We also created standard junctions for transcription terminators, a molecular stop sign for gene expression, said Dr. Guillaume Cambray, a BIOFAB team leader.

While the initial BIOFAB project was able to tame three types of core genetic parts, much more work remains. We ask that others expand upon the genetic grammar initiated here, to incorporate additional genetic functions and to translate the common rule set beyond E. coli, says Stanford professor and BIOFAB co-director Drew Endy. (Endy also serves as president of the BioBricks Foundation.)

The BIOFABs seed money came from the National Science Foundation, but this funding came only after 10 years of knocking on doors. Part of the difficulty was that the BIOFAB represented a fundamental engineering research project. Its not the kind of work that is suitable for a single graduate student thesis, and it wasnt economically practical for a biotechnology company to take it on. UC Berkeley professor and BIOFAB co-director Adam Arkin noted that, We knew that we would only be successful if we could bring together the skills represented by both academia and industry to establish a professional team that could specify and solve the fundamental engineering puzzles that slow the development of effective biotechnologies

The BIOFABs collaboration with not only the NSF, but also with industry, has been one of the keys to its success. Pre-competitive and unrestricted partnerships with industry were essential to guide the work and help secure and extend public funding, said UC Berkeley professor and BIOFAB advisor Jay Keasling. (Both Arkin and Keasling are also affiliated with Lawrence Berkeley Lab; Arkin is Director of the Physical Biosciences Division, and Keasling is an Associate Lab Director for Biosciences.)

Other partners came from civil society, including the BioBricks Foundation, a public-benefit organization that helps to advance best practices in the emerging field of synthetic biology. We were thrilled to help make all BIOFAB engineered parts free-to-use via the BioBrick Public Agreement and the public domain, said Holly Million, the foundations executive director.

The BIOFABs standardized parts are specific for E. coli but the grammar the way in which the rules are constructed for how the parts fit together should apply to nearly any organism; many of the BIOFABs rules for E.coli are expected to apply to other prokaryotes.

See more here:
Synthetic biologists standardize genetic parts to engineer cells

Recommendation and review posted by Bethany Smith

Public release date: 11-Mar-2013 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, March 11, 2013Consumption of energy drinks containing caffeine may have beneficial effects on exercise but probably not for mental function. The effects of pre-exercise caffeine consumption by trained cyclists on racing times and cognitive performance were measured and are reported in Journal of Caffeine Research, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Journal of Caffeine Research website at http://www.liebertpub.com/jcr.

Race performance improved for all study participants after consuming an energy drink, even if they already had an elevated blood caffeine level before the energy drink. Cycling times improved by an average of 3% for the group. David Gray Lassiter and coauthors from University of Texas at Austin also reported improvements in certain aspects of cognitive function, but these were probably not due to the energy drink. They present their findings in the article "Effect of an Energy Drink on Physical and Cognitive Performance in Trained Cyclists."

"While it is not certain from this one study whether energy drink improves physical performance, the study is important in pointing the way to further research in this area," says Jack E. James, PhD, Editor-in-Chief of Journal of Caffeine Research.

###

About the Journal

Journal of Caffeine Research: The International Multidisciplinary Journal of Caffeine Science is a quarterly journal published in print and online that covers the effects of caffeine on a wide range of diseases and conditions, including mood disorders, neurological disorders, cognitive performance, cardiovascular disease, and sports performance. The Journal explores all aspects of caffeine science including the biochemistry of caffeine; its actions on the human body; benefits, dangers, and contraindications; and caffeine addiction and withdrawal, across all stages of the human life span from prenatal exposure to end-of-life. Tables of content and a sample issue may be viewed on the Journal of Caffeine Research website at http://www.liebertpub.com/jcr.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Breastfeeding Medicine, Journal of Medicinal Food, and Journal of Child and Adolescent Psychopharmacology. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website at http://www.liebertpub.com.

Read the original:
Can energy drinks improve the physical and mental performance of cyclists?

Recommendation and review posted by Bethany Smith

Public release date: 12-Mar-2013 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, March 12, 2013The foodborne bacteria Listeria monocytogenes sickens about 2,500 people in the U.S. each year and many more worldwide, killing about 25-30% of those infected. Listeriosis is caused by eating food contaminated with L. monocytogenes, and current methods for detecting the bacteria are costly and time consuming. An innovative nanotechnology-based method for developing an inexpensive biosensor to detect the pathogen in food is described in Industrial Biotechnology, a peer-reviewed journal from Mary Ann Liebert Inc., publishers (http://www.liebertpub.com). The articles are available free on the Industrial Biotechnology (http://www.liebertpub.com/ind) website.

Vivian C.H. Wu, PhD led a group of scientists from University of Maine (Orono), National Chio Tung University, and Apex Biotechnology Corp. (Hsinchu, Taiwan), in producing a highly specific, antibody-based immunobiosensing strip with the potential for low-cost commercial development. Danielle Davis, et al. describes their work in the article "Gold Nanoparticle-Modified Carbon Electrode Biosensor for the Detection of Listeria monocytogenes (http://online.liebertpub.com/doi/full/10.1089/ind.2012.0033)."

The article is part of an IB Special Section on Nanobiotechnology, Part 2, led by Co-Guest Editors Norman Scott, PhD, Professor, Cornell University (Ithaca, NY) and Hongda Chen, PhD, National Program Leader, National Institute of Food and Agriculture, USDA (Washington, DC). In their Overview article "Nanoscale Science and Engineering for Agriculture and Food Systems (http://online.liebertpub.com/doi/full/10.1089/ind.2013.1555)," they describe the emerging opportunities and challenges for nanotechnology and nanomaterials research in industrial biotechnology.

The special section also includes two Review articles: "Time Analysis of Poly(Lactic-Co-Glycolic) Acid Nanoparticle Uptake by Major Organs Following Acute Intravenous and Oral Administration in Mice and Rats (http://online.liebertpub.com/doi/full/10.1089/ind.2012.0032)" by Lacey Simon and Cristina Sabliov, Louisiana State University (Baton Rouge, LA); and "Biomarker-Based Nanotechnology for the Improvement of Reproductive Performance in Beef and Dairy Cattle (http://online.liebertpub.com/doi/full/10.1089/ind.2012.0035)" by Peter Sutovsky and Chelsey Kennedy, University of Missouri-Columbia, MO.

Additional original research articles include "Pueraria lobata (Kudzu) Photosystem I Improves the Photoelectrochemical Performance of Silicon (http://online.liebertpub.com/doi/full/10.1089/ind.2012.0036)" by Darlene Gunther, Gabriel LeBlanc, David Cliffel, and G. Kane Jennings, Vanderbilt University (Nashville, TN); and "An Aptasensor Based on Polymer-Gold Nanoparticle Composite Microspheres for the Detection of Malathion Using Surface-Enhanced Raman Spectroscopy (http://online.liebertpub.com/doi/full/10.1089/ind.2012.0029)" by Francisco Barahona, Cameron Bardliving, Adrienne Phifer, John Bruno, and Carl Batt, Cornell University (Ithaca, NY) and Operational Technologies Corp. (San Antonio, TX).

"Nanoscale science continues to play a major role in catalyzing biotechnology innovation, yielding a broad spectrum of devices and products that are addressing many pressing social needs," says Larry Walker, PhD, Co-Editor-in-Chief and Professor, Biological & Environmental Engineering, Cornell University, Ithaca, NY.

###

About the Journal

Read the original:
Low-cost nano-biosensor to detect foodborne pathogen that causes listeriosis

Recommendation and review posted by Bethany Smith

BIOFABs directors Drew Endy (left) and Adam Arkin hope that their facility will help to industrialize synthetic biology.

Margot Hartford

The latest shopping website is open for business, offering unusual wares: DNA tools to help biologists to engineer life.

The DNA sequences which allow precise control of gene activity in the bacterium Escherichia coli are the first output of BIOFAB, based in Emeryville, California, which calls itself the worlds first biological design-build facility. Launched in 2009 with a US$1.4-million grant from the US National Science Foundation, BIOFAB aims to advance synthetic biology by creating standard biological parts in the form of DNA sequences that control gene expression. These standard sequences should allow biologists to engineer cells that can make medicines and perform other useful tasks simply by plugging in various sets of genes.

The sequences are meant to overcome a key barrier to synthetic biology: genes inserted into an organism do not behave predictably, even in such a well-understood workhorse as E. coli. You would think after a generation of genetic engineering, expressing genes with precision in an organism as well utilized as E. coliwould be pretty straightforward. It turns out its not, says BIOFAB co-director Drew Endy, a synthetic biologist at Stanford University in California.

For a cell to express a gene that is, transcribe it into an RNA molecule and then translate that RNA into a protein other sequences recognized by the cells machinery must precede it. A promoter sequence is needed to make an RNA transcript, and a ribosome binding site (RBS) is crucial for protein translation.

Over the past three decades, scientists have amassed collections of these sequences and used them to express genes in which they are interested. Some sequences tend to be strong and others weak, resulting in varying levels of RNA and protein being produced.

But a team led by Endy and BIOFAB co-director Adam Arkin, of Lawrence Berkeley National Laboratory in Berkeley, California, has found that the activities of those sequences are far from predictable. In two papers published online this week in Nature Methods1, 2, the team reports inserting many different combinations of promoters and RBS sequences in front of genes encoding fluorescent proteins, and then measuring the level of protein that was made. It was a bloody mess, says Arkin, with each promoterRBS combination having varying effects depending on the gene.

He and Endy also cite an earlier finding that a scientist hoping to express a protein at a particular level has just a 50% chance of producing the required amount within a factor of two. Such hit-or-miss expression poses a major challenge to synthetic biologists who would like to create genetic circuits involving dozens of genes.

As a solution, the BIOFAB team designed promoter and RBS sequences for E. colithat do not interfere with downstream DNA, so that their effects are independent of the specific gene they are paired with. The sequences should provide scientists with a much tighter grip on gene expression, offering around a 93% chance of hitting a desired level of expression within a factor of two2. Researchers can obtain the sequences for free online (see http://www.biofab.org/data), and Arkin says that some of his colleagues are already finding them useful.

View original post here:
DNA tool kit goes live online

Recommendation and review posted by Bethany Smith

Colon Cancer Pathological and Clinical Stages
Dr. Kozloff explains that although there are four specific stages of colon cancer, doctors often break the stages up into two stages: clinical and pathologic...

By: coloncancerdr

Excerpt from:
Colon Cancer Pathological and Clinical Stages - Video

Recommendation and review posted by Bethany Smith

JEFFREY BROWN: In California, researchers are sifting through a huge collection of genetic data that could be a key to unlocking vital information for doctors and patients.

NewsHour correspondent Spencer Michels reports.

SPENCER MICHELS: Every year, 240,000 men in America learn that they have prostate cancer. Reggie Watkins, a retired parole officer and a patient at Kaiser Permanente in Oakland, Calif., is one of them.

REGGIE WATKINS, Kaiser Patient: The first biopsy showed a slight cancer, slight amount of cancer. The second biopsy showed no cancer. I do think there's a genetic situation in my family. I'm not the only and my brother is not the only one in the family to have this problem.

SPENCER MICHELS: Until recently, Watkins' family history and his unique genetic makeup would have played a minor role, if any, in his medical care. But thanks in part to a massive, groundbreaking new study under way at Kaiser and the University of California, San Francisco, information gleaned from patients' genes may prove the key to identifying and treating a host of diseases.

NEIL RISCH, University of California, San Francisco: You know, you're not born to this world as a blank slate. You come into it with a certain genetic disposition.

SPENCER MICHELS: UCSF Professor Neil Risch, the lead genetic researcher, says that his project and others that compile vast amounts of genetic information are on the verge of revolutionizing medicine.

NEIL RISCH: We can actually look to see how the genes that somebody has and they have had since they were born interact with environmental factors that actually work together to either increase or decrease risk of, say, heart disease or cancer or a whole variety of things.

SPENCER MICHELS: More than 200,000 Kaiser patients in California over the last five years have volunteered saliva and blood samples for genetic analysis. Those samples are processed at this Kaiser lab using state-of- the-art robotic devices which extract the DNA.

CATHERINE SCHAEFER, Kaiser Permanente: This is the richest, largest, the most comprehensive data bank right now in the world.

Read the original post:
Researchers Aim to Unlock Genetic Data Goldmine for Vital Medical Information

Recommendation and review posted by Bethany Smith

Strange Materials with Mark Miodownik
Materials are a defining characteristic of society. The ages of civilization are named after materials and the development of new materials do more than simp...

By: TheRoyalInstitution

View original post here:
Strange Materials with Mark Miodownik - Video

Recommendation and review posted by Bethany Smith

Can You Build Muscle With Hardgainer Genetics
http://www.StackedNJacked.com - Click HERE for your FREE guide to getting Stacked N Jacked. http://dclaiborne.com/start-here - Click HERE for your FREE repor...

By: GenesisAthleticPerf

Visit link:
Can You Build Muscle With Hardgainer Genetics - Video

Recommendation and review posted by Bethany Smith

Debut DNA Genetics Exodus Kush
Debut of DNA Genetics Exodus Kush, taking some clones off this cute plant that is in the vegative phase. This Exodus Kush looks really healthy and I #39;m excite...

By: Matt Mernagh

Visit link:
Debut DNA Genetics Exodus Kush - Video

Recommendation and review posted by Bethany Smith

The Great Debate - What is Life?
http://www.thesciencenetwork.org Richard Dawkins, J. Craig Venter, Nobel laureates Sidney Altman and Leland Hartwell, Chris McKay, Paul Davies, Lawrence Krau...

By: TheScienceFoundation

Visit link:
The Great Debate - What is Life? - Video

Recommendation and review posted by Bethany Smith

15 hours ago Mar. 12, 2013 - 9:00 AM PDT

Spiral Genetics, a Seattle-based startup that helps researchers and others quickly analyze DNA sequence data, has raised $3 million in its first institutional round of funding.

The Series A round was led by venture firm DFJ and brings the startups total amount raised to $3.7 million. With the new funding, Adina Mangubat, Spiral Genetics co-founder and CEO, said her eight-person team plans to expand product development, as well as sales and marketing.

Mangubat said that when she and one of her co-founders, Becky Drees, first looked at the field of genomics, their plan was to launch a consumer-focused genetic testing service like 23andme. But as that company started launching its services, they decided to switch tacks.

We were looking at the industry and we wanted to do something really impactful that involved genomics and computing, she said. When they realized the speed and volume with which raw sequence data was being generated, she said, they spotted an opportunity in offering high-performance bioinformatics tools for analyzing it.

Companies like DNANexus also offer sequence analysis, and others might conduct the analysis in-house, but Mangubat said they envisioned a service that could shrink the turnaround time for researchers and others in industry deluged by data. Last month, Redwood City, Calif.-based Bina Technologies announced the commercial launch of its own genomic analysis platform and similarly touts a faster-than-ever service.

Mangubat and Drees teamed up with their third co-founder Jeremy Bruestle and started building a computing platform specifically intended to solve this kind of big data problem. Now, the company says, it can analyze a whole human genome in 3 hours, which is about 40 times faster than what it might take others.

Spiral Genetics customers run the gamut from academic researchers to corporations, Mangubat said. For example, while some clients may use their bioinformatics tool to tackle childhood cancer, others in agrigenomics could use it to sequence different strains of corn.

Along with the new funding, Spiral Genetics announced a new partnership with Omicia, an Emeryville, Calif.-based provider of clinical genome sequence interpretation tools.

Subscriber Content

Read more from the original source:
Big data bioinformatics startup Spiral Genetics raises $3M

Recommendation and review posted by Bethany Smith

LOS ANGELES, March 12, 2013 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, announced today that Thomas A. Bologna, Chairman and CEO, will present at the 25th Annual ROTH Conference in Laguna Niguel, CA.

Mr. Bologna's presentation is scheduled to begin at 4:00 p.m. PDT on March 19, 2013. Interested investors can access a live webcast of the presentation by going to the Investor Relations tab on the Response Genetics website: http://www.responsegenetics.com.

About Response Genetics, Inc.

Response Genetics, Inc. (the "Company") is a CLIA-certified clinical laboratory focused on the development and sale of molecular diagnostic testing services for cancer. The Company's technologies enable extraction and analysis of genetic information derived from tumor cells stored as formalin-fixed and paraffin-embedded specimens. The Company's principal customers include oncologists and pathologists. In addition to diagnostic testing services, the Company generates revenue from the sale of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The Company's headquarters is located in Los Angeles, California. For more information, please visit http://www.responsegenetics.com.

Forward-Looking Statement Notice

Except for the historical information contained herein, this press release and the statements of representatives of the Company related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995.

Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions, such as the ability of the Company, to provide clinical testing services to the medical community, to continue to expand its sales force, to continue to build its digital pathology initiative, to attract and retain qualified management, to strengthen marketing capabilities, to expand the suite of ResponseDX(R)products, to continue to provide clinical trial support to pharmaceutical clients, to enter into new collaborations with pharmaceutical clients, to enter into areas of companion diagnostics, to continue to execute on its business strategy and operations, to continue to analyze cancer samples and the potential for using the results of this research to develop diagnostic tests for cancer, the usefulness of genetic information to tailor treatment to patients, and other statements identified by words such as "project," "may," "could," "would," "should," "believe," "expect," "anticipate," "estimate," "intend," "plan" or similar expressions.

These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities Exchange Commission. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.

Read this article:
Response Genetics to Present at the 25th Annual ROTH Conference

Recommendation and review posted by Bethany Smith

SEATTLE, March 12, 2013 /PRNewswire/ --Spiral Genetics, a cloud-based big data bioinformatics company, announced today that it closed its Series A financing, led by venture capital firm DFJ. The new capital will help further Spiral Genetics' mission to create revolutionary tools that empower the bioinformatics community to solve the large-scale genomic data challenges of tomorrow. The company intends to use the funds to expand its bioinformatics engineering team, scale its sales and marketing efforts and accelerate product development.

In addition to its funding, Spiral announced its partnership with Omicia, a developer of scalable and fully integrated informatics systems specifically designed to interpret human genome sequences for research and clinical applications. The partnership leverages Omicia's Opal solution which is a variant analysis tool that empowers researchers and clinicians to analyze genomes and prioritize disease-causing variants.

"Our partnership with Spiral Genetics allows faster and more accurate interpretation of human genomes for clinical relevance; a critical bottleneck for adoption of genomes into clinical care and laboratory testing. In combination with Omicia's Opal system, our partnership will move us closer to a seamless solution from raw sequence data to clinically relevant genomic variants. Speed and user friendliness are critical for adoption of human genome sequencing," stated Martin G. Reese, Ph.D, Co-Founder, President and Chief Scientific Officer Omicia. The Opal tool is used by CLIA labs and clinical researchers and in combination with Spiral's platform is providing same-day analysis from raw reads to produce clinically relevant findings.

"Innovations in DNA sequencing have led to an explosion of data, which presents an enormous market opportunity," said Rachel Pike of DFJ. "These developments are only accelerating and will have real and lasting implications on drug development, R&D in agriculture, and biological production of chemicals and fuels. Spiral Genetics is a solution that will both manage and draw insight from these data, enabling the industry to keep up with constantly-accelerating technological progress."

The Spiral Platform offers the fastest cloud-based bioinformatics analysis available today. Their breakthrough approach accelerates the data processing time from days to hours, shrinking analysis time for a whole human genome at 40x coverage to 3 hours.

"We are thrilled to be backed by DFJ," stated Adina Mangubat, CEO of Spiral Genetics. "DFJ has consistently invested in industry leaders whose technologies are changing critical industry sectors. As more academic researchers and agro-genomic and pharmaceutical companiesincrease their use of genomic data, there's no doubt that a large-scale, focused bioinformatics toolkit to process and analyze genomic data will be vital. We are excited to be at the forefront of developing new solutions to these challenges."

About Spiral Genetics Spiral Genetics provides the fastest cloud-based bioinformatics analysis available today. Used by customers across a variety of industries including drug development and agriculture, Spiral's breakthrough approach accelerates data processing time from days to hours, allowing researchers to analyze a whole human genome from raw DNA sequence data to a fully annotated list of genetic variants in just 3 hours.

About DFJ DFJ is a venture capital firm that partners with extraordinary entrepreneurs who set out to change the world. Since 1985, DFJ and the DFJ Global Network have had $7B committed to their funds and have managed more than 400 portfolio investments, including AdMob, Baidu, Box, Skype, Hotmail, SpaceX, Tesla Motors, SolarCity, Twitter, Tumblr and Yammer. DFJ works with companies at seed, early and growth stages, with the goal of creating iconic and lasting businesses. DFJ pioneers investing in emerging markets including consumer and enterprise information technology, digital media, and disruptive technologies. The DFJ Global Network is a federation of 16 independent venture funds operating on four continents that cooperate on investment diligence and co-investing. Learn more at dfj.com.

About Omicia, Inc. Based in the San Francisco Bay Area, Omicia develops scalable and fully integrated informatics systems specifically designed to interpret human genome sequences for research and clinical applications. Omicia's mission is to help research scientists, clinicians and patients better understand the most relevant information from personal genome sequences and their potential medical consequences. Omicia is funded with private investments and a series of Small Business Innovation Research (SBIR) grants from the National Institutes of Health. For more information, please visit http://www.omicia.com

Follow this link:
Spiral Genetics Closes $3 Million in Funding Led by DFJ and Announces Partnership with Omicia

Recommendation and review posted by Bethany Smith

Spinal Cord Injury Treatment and Symptoms
XXXXXX #9669; Spinal Cord Injury treatment mdash; Finding the right information about Spinal Cord Injury treatment symptoms, is crucial to managing Spinal Cord Injur...

By: MainMDcom

See the article here:
Spinal Cord Injury ¦ Treatment and Symptoms - Video

Recommendation and review posted by sam

LONDON (SHARECAST) - ReNeuron Group has won two grants worth 1.2m pounds to develop its stem cell therapy.

The grants were awarded by the UK Biomedical Catalyst, a programme of public funding jointly managed by the Technology Strategy Board and the Medical Research Council.

The first award of 0.4m will be used for ReNeurons ReN009 stem cell therapy candidate for critical limb ischaemia, a severe blockage in the arteries which markedly reduces blood-flow to the extremities including hands, feet and legs.

The second award of 0.8m relates to the company's ReN003 stem cell candidate for the treatment of retinitis pigmentosa, an eye disease in which there is damage to the retina.

Michael Hunt, the Chief Executive Officer of ReNeuron, said: "We are delighted to have been successful in winning the two grants we applied for in the current round of the Biomedical Catalyst funding competition.

"This highly competitive scheme involves a rigorous peer review of applicants' technologies and commercial development plans.

"In common with other awardees, we therefore regard the grants as representing a strong independent endorsement of ReNeuron's world-class stem cell development capabilities which we hope will eventually lead to the wide-scale treatment of disease conditions where there is currently a very large unmet medical need."

Shares rose 0.86% to 2.94p at 08:52 Monday.

RD

See more here:
ReNeuron Group wins grants for stem cell therapy development

Recommendation and review posted by simmons